We propose that BCL11B-associated phenotypes may contribute to neuropathology most significantly in HD and SCZ and identify modulation of PKA-dependent Ca2+ signals and protein phosphorylation as potential new therapeutic targets in the striatum. This evidence concerns the gene BCL11B and Huntington disease.